IBIO, INC. Form ARS: Annual report to security holders
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2026-09-04: Form ARS; Period of report 2026-06-30; Description ARS; Document ibio-20260630xars.pdf.
- 2025-10-06: Form ARS; Period of report 2025-06-30; Description ARS; Document ibio-20250630xars.pdf.
- 2024-10-10: Form ARS; Period of report 2024-06-30; Description ARS; Document ibio-20240630xars.pdf.
- 2023-10-26: Form ARS; Period of report 2023-06-30; Description ARS; Document ibio-20230630xars.pdf.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2026-09-04 | ARS | 2026-06-30 | ARS | ibio-20260630xars.pdf |
| 2025-10-06 | ARS | 2025-06-30 | ARS | ibio-20250630xars.pdf |
| 2024-10-10 | ARS | 2024-06-30 | ARS | ibio-20240630xars.pdf |
| 2023-10-26 | ARS | 2023-06-30 | ARS | ibio-20230630xars.pdf |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |